Abstract
Schizophrenia is a severe mental disorder characterized by positive, negative, and cognitive symptoms. Cognitive symptoms are a kind of symptoms with high incidence and great impact on patients. There is no effective treatment in clinical practice. N-methyl-d-aspartic acid (NMDA) receptor hypofunction may be an important cause of cognitive symptoms. MK-801 (also named Dizocilpine), a noncompetitive antagonist of NMDA receptor, is often used to construct a model of NMDA receptor dysfunction. In terms of treatment, environmental enrichment (EE) as an environmental intervention can effectively improve the symptoms of cognitive impairment in rodents. In this paper, we first briefly introduce the background of cognitive symptoms and EE in schizophrenia, and then investigate the manifestations of MK-801 induced cognitive impairment, the improvement of EE on these cognitive impairments based on the MK-801 induced schizophrenia rodent models, and the possible mechanism of EE in improving cognitive symptoms. This article reviews the literature in recent years, which provides an important reference for MK-801 to construct a cognitive symptom model of schizophrenia and the mechanism of EE in improving cognitive symptoms of schizophrenia.
Introduction
Schizophrenia (SCZ) is a severe mental disease characterized by positive symptoms (delusions, hallucinations), negative symptoms (anhedonia, social withdrawal), and cognitive symptoms (learning, and memory disorders), which affects about 1% of the world's population. It is one of the most serious mental disorders (Jauhar et al., 2022). Cognitive symptoms are the core symptoms of schizophrenia, which have a great impact on the quality of life of patients, with a high incidence in patients, and up to 98.1% of patients have cognitive disorders (Wu et al., 2021). Moreover, there is a lack of effective treatment for cognitive symptoms. Clinically, anti-schizophrenic drugs are effective for positive symptoms, but the efficacy of drugs will reduce when treating negative symptoms. However, the therapeutic effect of these drugs on cognitive symptoms is negligible (Prades et al., 2017). Due to the great impact on patients and the lack of effective treatment, cognitive symptoms have attracted more and more attention in the latest research on schizophrenia. The pathological mechanism of schizophrenia is complex. Since the 1980s, clinical studies and animal model studies have suggested that schizophrenia is closely related to the impairment of glutamate transmission in the brain. Therefore, the glutamate hypothesis has been proposed, which suggests that NMDA receptor may be the key molecules of schizophrenia (Hansen et al., 2018). Decreased mRNA expression levels of NMDA receptor and abnormal receptor binding sites can cause glutamate dysfunction, resulting in cognitive deficits (Li et al., 2018). Clinical studies have found that NMDA receptor antagonists in healthy individuals can induce cognitive impairment symptoms similar to those of schizophrenia patients and can aggravate the original symptoms of schizophrenia (Adell, 2020). Laboratory animal model studies have also shown that NMDA receptor antagonists can induce cognitive impairment symptoms in animal models, which have been widely used in the study of schizophrenia (Vales and Holubova, 2021).
Building animal models is the most common way to study schizophrenia. Based on the inducement of schizophrenia, common animal models of schizophrenia include developmental models, genetic models, and drug models (Winship et al., 2019). Among them, the drug models are the most common animal models and non-competitive antagonists of NMDA receptor are commonly used to construct drug models (Winship et al., 2019). MK-801 is a non-competitive antagonist of the NMDA receptor. Compared with other commonly used non-competitive antagonists of NMDA receptor, such as phencyclidine and ketamine, MK-801 has a stronger inhibitory effect on NMDA receptor (Wallach et al., 2016), with higher affinity and specificity (Nakazawa and Sapkota, 2020). In addition, MK-801 can simulate the typical positive symptoms, negative symptoms, and cognitive symptoms of schizophrenia in animals at the same time, which is considered to be one of the best drugs for schizophrenia modeling (Shahzad et al., 2017).
Environmental enrichment (EE) is an environmental intervention that can limit the presentation of schizophrenia symptoms in a rat model of the disorder (Zhu and Grace, 2021). Due to the obvious limitations of drug treatment, non-drug means such as cognitive behavioral therapy (Batinic, 2019) and exercise therapy (Girdler et al., 2019) to control schizophrenia are gradually being paid attention to. EE can provide rodents with an environment that promotes physical activity, cognitive activity, and social interaction, which can have beneficial effects on the structure and function of the brain, behavior, cognition, and other aspects (Livingston-Thomas et al., 2016; Gubert and Hannan, 2019). The key of EE is offering an innovative environment, social contact, and exercise facilities (Crofton et al., 2015). The basic experimental settings include feeding the rodents in the larger community and bigger cages, adding some toys in the cage, nesting material, pipes and other items used for the rats or mice climbing and hiding, and regular change of squirrel cage inside decorate (Kempermann, 2019). EE has been proven to improve behavioral abnormalities in rodent models of schizophrenia and improve complex cognitive functions such as learning and memory (Burrows et al., 2015).
This article will review the cognitive symptoms of MK-801 induced in rodents, the effect of EE on cognitive impairment behavior, and the possible mechanisms.
MK-801 induced cognitive impairment in rodents with schizophrenia
Cognitive impairment is the core feature of schizophrenia, which seriously affects the quality of life of patients (Maas et al., 2020). NMDA receptor is a ligand-gated ionic glutamate receptor mainly present in the central nervous system, and NMDA receptor-mediated glutamate transmission is believed to be related to cognitive function, especially in learning and memory (Khakpoor et al., 2021). MK-801 is a noncompetitive antagonist of the NMDA receptor, which is considered to be a cognition impairer, a compound that disrupts cognitive function, causing learning, memory, and sensorimotor gating dysfunction (Rahati et al., 2016). These defective behaviors can be detected by the new object recognition (NOR) experiment, Morris water maze, object-in-place experiment, passive avoidance (PA) test, eight-arm radial maze, and prepulse inhibition (PPI). The results can be used to assess whether the cognitive function of rodents is normal.
There are a variety of classification methods for memory function, one of which can divide memory function into working memory and reference memory. Working memory includes short-term memory and spatial memory, etc., while reference memory is considered a long-term and permanent memory or habit (Bernaud et al., 2021). Different experiments detect the two kinds of memory abilities differently. NOR, Morris water maze and object-in-place experiment are used to detect working memory defects, PA test and eight-arm radial maze can detect not only working memory but also reference memory. In the following, the MK-801 induced cognitive deficit behaviors will be reviewed in order of experimental detection of different memories (see Table 1).
Table 1
| Experiment | Drug intervention | Sex/strain | Behavior change | EE intervention | Behavior improvement | Bibliography |
|---|---|---|---|---|---|---|
| NOR | Chronic 0.1 mg/kg MK-801 | Male and female C57BL/6 neonatal mice | Discrimination index declines | Plataki et al., 2021 | ||
| Acute 0.2 mg/kg MK-801 | Male C57/BL6J mice | Discrimination index declines | Prades et al., 2017 | |||
| Chronic 0.5 mg/kg MK-801 | Male and female Long Evans neonatal rats | Discrimination index declines | 18 days EE treats during P55-P73 | The discrimination index of the MK-801 treated group and control group increased | Murueta-Goyena et al., 2018 | |
| Chronic 1 mg/kg MK-801 | Male and female Wistar neonatal rats | Recognition index declines | EE treats on the first day after birth until the end of the experiment | The male behavior improves significantly, but the female does not improve | Faatehi et al., 2019 | |
| Morris water maze | Chronic 0.5 mg/kg MK-801 | Male Long Evans neonatal rats | Increase in swimming distance, increase in time spent | EE treats on the first day after birth until the end of the experiment | Swimming distance and time spent decrease | Murueta-Goyena et al., 2019 |
| Chronic 1 mg/kg MK-801 | Male Wistar neonatal rats | Increase in swimming distance, increase in time spent | EE treats on the first day after birth until the end of the experiment | Swimming distance and time spent decrease in the MK-801 treated group and control group | Nozari et al., 2014 | |
| Chronic 0.25 mg/kg MK-801 | Male Balb/c neonatal mice | Increase in swimming distance, increase in time spent | EE treats on the 21st day after birth until the end of the experiment | EE does not rescue the impaired performance of spatial learning ability | Akillioglu et al., 2012 | |
| Object- in-place | Chronic 0.5 mg/kg MK-801 | Male Long Evans neonatal rats | Discrimination index declines | EE treats on the first day after birth until the end of the experiment | Discrimination index increases | Murueta-Goyena et al., 2019 |
| PA test | Acute 0.15 mg/kg MK-801 | Male Wistar rats | Long-term memory is impaired | Zahiri et al., 2021 | ||
| Chronic 0.25 mg/kg MK-801 | Male Wistar neonatal rats | Both long-term and short-term memory are normal | Kocahan et al., 2013 | |||
| Chronic 1 mg/kg MK-801 | Male Wistar neonatal rats | Long-term memory is impaired, short-term memory is normal | EE treats on the first day after birth until the end of the experiment | Incubation period increases and long-term memory improves | Rahati et al., 2016 | |
| Eight-arm radial maze | Chronic 0.5 mg/kg MK-801 | Male Wistar rats | Working memory and reference memory are impaired | Li et al., 2019 | ||
| Acute 0.08 mg/kg MK-801 | Male Long-Evans rats | Spatial working memory is impaired | Nishiyama et al., 2017 | |||
| Chronic 1 mg/kg MK-801 | Female Wistar neonatal rats | Working memory is impaired, reference memory is normal | EE treats on the first day after birth until the end of the experiment | No improvement in impaired working memory | Nozari et al., 2015a | |
| PPI | Acute 0.2 mg/kg MK-801 | Male C57/BL6J mice | PPI decreases at 81, 85, 90 dB | Prades et al., 2017 | ||
| Chronic 1 mg/kg MK-801 | Male and female Wistar neonatal rats | Male and female rats show PPI deficiency | EE treats on the first day after birth until the end of the experiment | PPI deficiency is improved in male rats, but not in female rats | Nozari et al., 2015b |
MK-801 induced cognitive symptoms of schizophrenia in rodents and improvement of cognitive symptoms by EE.
NOR is an experiment that uses the rodents' stronger tendency to explore new objects to assess their working memory. If the animal has a good memory function, it will spend more time exploring new objects, whereas the animal with memory problems will spend more time on old objects. This experiment is mainly used to measure hippocampal function as well as the function of other cortical regions involved in object recognition, such as the prefrontal cortex (Denninger et al., 2018). Chronic treatment with 1 mg/kg MK-801 in the early stage of Wistar neonatal rats can reduce the recognition index in NOR, which shows that the time to explore the novel objects is decreased, while the time of exploring the old objects is increased. And the performance of male and female Wistar neonatal rats is similar (Faatehi et al., 2019). Treatment of C57BL/6 neonatal mice with low concentrations of MK-801, such as 0.1 mg/kg, has similar effects (Plataki et al., 2021). However, it has also been argued that chronic MK-801 administration induces working memory deficits in NOR with a threshold of administration concentration, and only concentrations higher than 0.5 mg/kg can successfully induce working memory deficits (Murueta-Goyena et al., 2018). In addition, the time of MK-801 administration also affects the NOR performance. For example, C57BL/6 neonatal mice show impaired discrimination index when MK-801 is administered on postnatal days 7–14, but there is no significant difference in NOR results between MK-801 treated and control mice when MK-801 is administered on postnatal days 11–15. This suggests that there is a time window for the effect of MK-801 on cognitive function (Plataki et al., 2021). In addition, acute MK-801 treatment also reduces the discrimination index of male C57/BL6J mice (Prades et al., 2017).
Morris water maze is an experiment to access learning and spatial memory by finding an escape route in the pool. Spatial memory is a type of working memory. If the learning and memory function is normal, the rodents will spend less time and swim less distance from being put into the water maze to boarding the platform after the they were trained for several days (Lissner et al., 2021). Compared with the control group, the Long Evans neonatal rats in the MK-801 treatment group take more time to find the hidden platform and have a longer swimming distance, indicating that their spatial learning ability is impaired (Murueta-Goyena et al., 2019). Treatment of adult C57BL/6 mice with MK-801 results in similar impaired spatial learning (Xiao et al., 2019).
Object-in-place experiment is an experiment to detect the spatial location memory of objects. The principle is that rodents will spontaneously remember the location of objects in space. When the original object's location moves, they will spend more time exploring the moved object (Aggleton and Nelson, 2020). The spatial location memory is also a kind of working memory. The discrimination index of Long Evans neonatal rats in the MK-801 treatment group is significantly reduced, and the object location memory is impaired (Murueta-Goyena et al., 2019).
The PA test is an experiment to evaluate working memory and reference memory function. The experimental device is composed of a light room and a dark room. During the training process, the rat or mouse will be put into the light room first, and a plantar shock will be given to them after they enter the dark room. Tests performed 2 h after training are used to assess short-term memory, whereas longer tests such as 24 h later are used to assess long-term memory. Short-term memory and long-term memory, respectively belong to working memory and reference memory (Kruk-Slomka and Biala, 2016). PA test only requires short-term training, which avoids memory overlap between experimental and training stages, but electrical stimulation can cause some harm to animals. The results of the PA test show that MK-801 can cause the impairment of PA memory and shorten the latency entering a dark room, and the response effect of the PA test to MK-801 is dose-dependent (van der Staay et al., 2011). Chronic treatment of Wistar neonatal rats with 1 mg/kg MK-801 mainly shows long-term memory impairment, with little effect on short-term memory (Rahati et al., 2016), but some studies also find that chronic treatment with 0.25 mg/kg MK-801 has no effect on the PA memory. There is no significant difference in short-term memory and long-term memory compared with the control group (Kocahan et al., 2013). Acute MK-801 administration results in a significantly shorter latency to enter the dark room when tested at 24 h, 48 h, and 10 d after training, indicating impairment of long-term memory in Wistar rats (Zahiri et al., 2021).
The eight-arm radial maze is an experiment used to assess working memory and reference memory (Mei et al., 2020). In experiments, rodents tend to explore the arm of the maze with food, and correct behavior means that they visit each arm of the maze with food only once (Kurzina et al., 2020), entering the arm without food indicates faulty reference memory, and re-entering the visited arm indicates faulty working memory (Kim et al., 2018). Chronic MK-801 treatment can damage both working memory and reference memory in male Wistar rats (Li et al., 2019), but chronic MK-801 treatment can only damage working memory and has no effect on reference memory in female Wistar rats. The reason for this situation may be that estrogen in the brain of female rats plays a neuroprotective role (Nozari et al., 2015a). Acute MK-801 treatment also increases the number of errors during exploration and impaired spatial working memory (Nishiyama et al., 2017). Different processing time of MK-801 has different effects on memory. The earlier the processing time, the greater the adverse effect. This suggests that the disruption of learning and memory by MK-801 results from neurodevelopmental interference, and the early postnatal period is critical for the development of pathways that encode learning and memory (Furuie et al., 2019). The number of arms in the radial maze is variable, some experiments apply the four-arm radial maze (Sampedro-Piquero et al., 2018), and some experiments apply the twelve-arm radial maze (MacQueen and Young, 2020), but the contents tested are similar, which are working memory and reference memory.
PPI is a measure of sensorimotor gating function, which is used to detect deficits in information processing ability and inhibition function. Patients with schizophrenia have impaired sensorimotor gating systems and have PPI deficiency, which is essential for normal cognitive processes. PPI is operated by giving a weak non-startle stimulus 30 to 500 ms before the startle reflex is induced by the auditory source stimulus, and the non-startle stimulus will increase the attenuation amplitude of the startle reflex (Li et al., 2021). After chronic administration of MK-801 to Wistar neonatal rats, PPI defects are observed in both male and female rats on postnatal days 28–30 (Nozari et al., 2015b). Acute MK-801 treatment also induces PPI defects, and PPI is significantly reduced to 81,85 and 90 dB (Prades et al., 2017).
EE improved the cognitive symptoms of schizophrenia induced by MK-801
EE is a behavioral paradigm that can stimulate cognitive function, and cognitive stimulation in rodents can be achieved by adding new items or rearranging existing items in the cage, thus positively affecting cognitive behavior (Zhu and Grace, 2022). EE can improve the positive, negative, and cognitive symptoms of MK-801 induced schizophrenia. But the improvement of cognitive symptoms is more obvious, which can prevent the spatial learning and memory defects induced by MK-801. And EE is also beneficial to the cognitive function of normal rodents (Nozari et al., 2014). The processing time of EE is flexible, which can be processed in neonatal rodents (Faatehi et al., 2019), in adolescent rodents (Akillioglu et al., 2012), and in adult rodents (Murueta-Goyena et al., 2018). The processing of EE at different stages has a positive effect on the cognitive behavior. The following will review the improvement of EE in MK-801 induced cognitive symptoms in schizophrenia (see Table 1).
In the NOR experiment, EE treatment of Wistar rats can completely reverse the effect of MK-801 on the recognition index of male Wistar rats, but the effect on the novel object exploration ability of female Wistar rats is not obvious (Faatehi et al., 2019). In addition, short-term EE treatment in early adulthood can restore the recognition memory of male Long Evans rats in the MK-801 treatment group, improve cognitive function, and increase the discrimination index. Moreover, EE treatment also has a benign effect on normal Long Evans rats and can increase the discrimination index of control Long Evans rats (Murueta-Goyena et al., 2018).
In the Morris water maze, EE treatment groups show normal spatial learning ability, and the swimming distance and time taken to reach the positioning platform are significantly reduced, indicating that the memory of Long Evans rats is improved (Murueta-Goyena et al., 2019). In addition, EE also enhances the completion efficiency of the Morris water maze task in the control groups, indicating that EE can also increase the cognitive function of normal Wistar rats (Nozari et al., 2014). However, some experiments find that EE treatment after 10 days of MK-801 administration does not reverse the abnormal behavior in the Morris water maze, possibly because MK-801 has caused irreversible negative effects at this time (Akillioglu et al., 2012).
In the Object-in-place experiment, early EE processing will cause Long Evans rats to spend more time exploring the moving object, and the discrimination index is significantly improved, indicating that EE can restore the memory deficit (Murueta-Goyena et al., 2019).
In the PA test, EE treatment can improve long-term memory and increase the latency in the MK-801 treatment groups to enter the dark room. At the same time, it also has a positive effect on normal Wistar rats and can increase the latency in the control groups to enter the dark room (Rahati et al., 2016).
In the eight-arm radial maze, EE can improve the cognitive impairment symptoms and improve the correct rate of completing the maze task (Cortese et al., 2018). However, there are few studies on EE in MK-801 induced learning and memory impairment in rodents. At present, it is only found that EE can' t improve the symptoms of working memory defects in female Wistar rats, which may be related to the characteristics of the experiment itself on the one hand, and the gender of the rats on the other hand (Nozari et al., 2015a).
In PPI experiments, EE can improve PPI deficiency in male Wistar rats, but not in female Wistar rats, and prolonging EE processing time does not affect PPI improvement. The difference in EE improving PPI may be due to the effect of estrogen in female Wistar rats, which may enhance neuronal discharge and affect PPI regulation (Nozari et al., 2015b).
In the above experiments, the improvement of cognitive symptoms of male and female rodents with EE is different, and this gender difference may be related to the difference in sex hormones. Female animals have more estrogen secretion, and estrogen can affect the cognitive behavior and neuronal placement. Moreover, the metabolism of MK-801 in female rodents is slow, and the concentration of MK-801 in female is higher than that in male, so MK-801 has a great influence on female rodents and their behaviors are not easy to improve (Faatehi et al., 2019).
EE can improve the cognitive symptoms of MK-801 induced schizophrenia, including alleviating the learning, memory, and sensory-motor gating dysfunction in the NOR test, Morris water maze, Object-in-place test, PA test, and PPI test in rodent models. However, late EE treatment can't improve the spatial learning ability in the Morris water maze, and EE does not improve the working memory deficit in the eight-arm radial maze test, and the effect of EE on cognitive symptoms in female and male rodents is inconsistent, indicating that EE does not improve the cognitive impairment comprehensively.
The mechanism of EE in improving cognitive symptoms
Noncompetitive inhibition of the NMDA receptor by MK-801 can induce cognitive symptoms of schizophrenia, but NMDA receptors are widely distributed. As a second messenger, Ca2+ caused by NMDA receptor activation participates in many signaling pathways, and the mechanism of action is complex. At present, the specific mechanism of action of MK-801 in inducing cognitive symptoms in schizophrenia is not fully understood. It is also true for EE improving the schizophrenia-like cognitive symptoms induced by MK-801 in rodents. It is generally believed that EE exposes them to more sensory stimuli, which increase the expression of neurotrophic factors, and promote cell proliferation, cell survival, and dendritic maturation, thereby enhancing cognitive function (Ramírez-Rodríguez et al., 2021).
In the MK-801 induced cognitive impairment rodent models of NMDA receptor dysfunction, EE affects the expression of neurons, glial cells, and proteins, and improves the cognitive symptoms in a variety of ways. The following will review the possible mechanisms (Figure 1).
Figure 1
Neural activity in MK-801 and MK-801+EE treated group. EE can promote the expression of BDNF and improve the signaling function of BDNF-TrkB. EE can rescue the blocking effect of MK-801 on NMDAR in interneurons, promote the expression of NMDAR subunits, PSD-95, and GAD 67, and promote GABA neurotransmitter synthesis. EE has a neurorepair effect, which can increase the number of PV+ and SST+ GABAergic neurons and increase the output of inhibitory signals. EE can rescues the regulation of glutamate by astrocytes, increase the number of GFAP positive cells and decrease the number of S100B positive cells. EE can activate Wnt/β signaling pathway in oligodendrocytes and promote myelin synthesis.
The effect of EE on neurons
Neurons are the main component of the nervous system and a core carrier to exert neuroregulatory function. EE regulates a variety of neurons, increases neuronal plasticity, and promotes neuronal development, to improve the cognitive symptoms of schizophrenia (Ratajczak et al., 2015). MK-801 affects cortical function by reducing the activity of inhibitory interneurons, thereby affecting cognitive function. EE can block the effect of MK-801 on interneurons.
GABA is the main inhibitory neurotransmitter in the central nervous system, which is involved in the excitation/inhibition balance of neuronal activity (Sears and Hewett, 2021). Studies have shown that the expression level of GABA membrane transporters, the density of GABAergic interneurons, and the concentration of GABA in cerebrospinal fluid are reduced in patients with schizophrenia (Marques et al., 2021). MK-801 will preferentially target and block the NMDA receptors on GABAergic parvalbumin (PV) positive interneurons, leading to the decrease of GABAergic neuron activity, reducing the inhibitory effect on pyramidal neurons, and then leading to the increase of cortical excitability (Tarrés-Gatius et al., 2022). The dysfunction of the GABAergic system may be the etiology of cognitive symptoms in schizophrenia. Blocking NMDA receptor in the neonatal period can affect the GABAergic system through multiple mechanisms. MK-801 can reduce the number of PV+ GABAergic interneurons in the hippocampus and PFC, and EE treatment can partially restore the number of these neurons, increasing the output of inhibitory signals (Murueta-Goyena et al., 2018). Somatostatin-positive (SST+) interneurons are also involved in the transmission of inhibitory signals. Their inhibitory effect can regulate sensory and cognitive functions. EE has a nerve repair effect, which can restore the number of SST+ interneurons in the mPFC and hippocampus of mice and improve cognitive function. However, EE does not affect the number of SST+ interneurons in control groups (Murueta-Goyena et al., 2020).
Axon initial segment (AIS) is the initiation site of action potentials and plays a major role in cell excitability. MK-801 can shorten the AIS in the prefrontal cortex, and the mechanism may be that MK-801 causes the inhibition of inhibitory interneurons on the cortex to weaken. The vertebral neurons in the prefrontal cortex are excited, and the AIS is compensatory shortened. EE treatment can increase the plasticity of AIS in the frontal cortex and also prevent MK-801 induced shortening of AIS (Nozari et al., 2017).
The effect of EE on glial cells
Schizophrenia may involve changes in a variety of glial cells in the brain. Oligodendrocytes are myelinating cells of the central nervous system, myelination in the prefrontal cortex is the basis of normal cognitive function, and myelination depends on the activation of NMDA receptor on oligodendrocytes (Dietz et al., 2020). MK-801 blocks NMDA receptor and inhibits oligodendrocyte activation, thereby reducing myelination in the brain (Lundgaard et al., 2013). EE affects oligodendrocytes and promotes myelination by activating the Wnt/β-catein signaling pathway, increasing Akt and MBP expression and other pathways (Gao et al., 2022).
Astrocytes can synthesize and recycle neurotransmitters, secrete neuromodulators, and participate in the synaptic transmission process. The cell density and morphology of astrocytes in schizophrenia patients are changed, and the expression of cell markers is dysregulated (Notter, 2021). Astrocytes are involved in the metabolism of glutamate in the central nervous system, which can maintain glutamate homeostasis through the uptake and release of glutamate, maintain normal neuronal function and prevent glutamate excitotoxicity (Mahmoud et al., 2019). Pathological changes of astrocytes in the prefrontal cortex are related to cognitive impairment in schizophrenia. GFAP and S100B are two astrocyte markers. MK-801 can interfere with the function of normal astrocytes, reducing the expression of GFAP and increasing the expression of S100B (Rahati et al., 2016). But some studies have found that repeated high doses of MK-801 increased GFAP expression in the hippocampus, which suggested astrocytes were activated by MK-801. It may increase the synthesis of BDNF in the astrocytes. This is a potential action of astrocyte compensatory effect induced by MK-801 (Yu et al., 2015). Early EE corrected MK-801 induced cognitive and behavioral deficits, significantly increased the number of GFAP-positive cells in the prefrontal cortex, and significantly reduced the number of S100B-positive cells (Rahati et al., 2016). Alternatively, EE can also increase the number of GFAP-positive astrocytes in the hippocampus (Zhang et al., 2021).
Effect of EE on neurotrophic factors
Brain-derived neurotrophic factor (BDNF) is a protein synthesized and secreted by neurons and involved in the growth and differentiation of neurons. The abnormality of BDNF is closely related to schizophrenia and plays a key role in learning and memory. The levels of BDNF in blood, cerebrospinal fluid, and different brain regions of schizophrenia patients are low (Harb et al., 2021). Tyrosine kinase B (TrkB) is a high-affinity receptor for BDNF. Binding of BDNF and TrkB affects neuronal function through the signaling cascade of target tissues (Mehrotra et al., 2022). Studies have shown that MK-801 can not only reduce the expression level of BDNF in prefrontal cortex and hippocampus (Yu et al., 2019), but also reduce the expression of TrkB and affect BDNF-TRKB signaling (Guo et al., 2020). EE treatment can increase the expression of BDNF and improve the signaling function of BDNF-TrkB (Murueta-Goyena et al., 2020). However, early EE treatment can improve the MK-801 induced reduction of BDNF in the hippocampus of male rodents, but it can't improve the reduction of BDNF in female, which may be the reason why EE does not significantly improve NOR in female rodents. In addition, EE also increases the expression level of BNDF in the control groups (Faatehi et al., 2019). In addition to BDNF, EE can also promote the expression of various neurotrophic factors, including nerve growth factor (Zhang et al., 2018), vascular endothelial growth factor (Rostami et al., 2021), and glial derived neurotrophic factor (Takuma et al., 2014), and improve cognitive symptoms in mice.
Effect of EE on other proteins expression
In addition to BDNF, EE also has an effect on the expression of other proteins. EE can promote the expression of NMDA receptor in the hippocampus of neonatal rodents treated with MK-801. NMDA receptor in the central nervous system mainly consist of tetramers of GluN1 and GluN2A/GluN2B subunits (Benske et al., 2022). MK-801 can down-regulate the expression of the NR1 subunit of the NMDA receptor in the hippocampus, and EE treatment can restore the expression level of NR1. In addition, EE can promote the expression of NR2A and NR2B subunits of the NMDA receptor (Murueta-Goyena et al., 2019). Specific inactivation of the NR1 subunit gene of the NMDA receptor in the CA1 region of the hippocampus leads to memory impairment, and mouse with overexpression of the NR2B subunit show better learning and memory abilities (Grilli et al., 2009). PSD-95 is a postsynaptic protein that regulates the expression of the NMDA receptor. EE treatment can rescue the decrease in PSD-95 expression induced by MK-801, indicating that EE will promote the neurotransmission effect of the NMDA receptor by affecting protein expression (Murueta-Goyena et al., 2019).
MK-801 can also significantly down-regulate a variety of GABA-related proteins including GAD65 (encoding glutamate decarboxylase 65), SYNPR (encoding synaptoporin), GAT3 (encoding sodium and chloride dependent GABA transporter 3), SN1 (encoding sodium coupled neutral amino acid transporter 3), DBI (encoding acyl-CoA binding protein), and CPT1A (encoding carnitine O-palmitoyltransferase 1), which are involved in the process of GABA synthesis, release, reuptake, and recruitment to maintain GABA function and homeostasis (Wang et al., 2021). Among them, glutamic acid decarboxylase 67 (GAD 67) is a GABA synthase. MK-801 can reduce the expression of GAD 67 in the hippocampus, leading to abnormal GABAergic system function, and EE can increase the expression of GAD 67 and promote the recovery of the GABAergic system (Murueta-Goyena et al., 2018).
Conclusion
Cognitive symptoms are one of the core symptoms of schizophrenia, but there is no effective treatment in clinical practice. The research on cognitive symptoms of schizophrenia is a hot topic nowadays. EE is an environmental intervention and has a significant improvement effect on cognitive symptoms. EE can alleviate a series of learning and memory deficits induced by MK-801, including NOR and Morris water maze. In this review, we summarize the recent literature on MK-801 induced cognitive impairment in rodents, the ameliorating effects of EE on cognitive impairment, and the possible mechanisms involved. After years of research, although people have a certain understanding of the mechanism by which MK-801 induces cognitive symptoms in schizophrenia and EE improves cognitive impairment, there are still some contradictions and problems to be solved in research. For example, in NOR, it is suggested that MK-801 administration above the threshold of 0.5 mg/kg can successfully induce working memory deficits, but some experiments can successfully induce working memory deficits by 0.1 mg/kg MK-801. In the PA test, the damage to long-term memory and short-term memory is different with different concentrations and ways of MK-801 administration. Rodents of different genders have different responses to MK-801 and EE, which may be related to the secretion of estrogen and the metabolism of MK-801, but the specific mechanism remains to be studied. Alternatively, although EE improves experimentally in response to abnormal cognitive behavior, it is still not possible to determine to what extent it plays a role during treatment and which components of EE are more effective in treatment. As an environmental intervention, EE can't completely control the symptoms of cognitive impairment in schizophrenia, and it is currently only used as a preventive method. Therefore, the research on cognitive symptoms of schizophrenia still has a long way to go. It is believed that with in-depth research, new pathological mechanisms will continue to emerge, and new treatment methods will be more perfect to prevent and control the occurrence and development of the disease, to bring good news to patients suffering from schizophrenia.
Funding
This study was supported by the Natural Science Foundation of China (82071536 to WW), Shaanxi Provincial Key Research and Development Program (2020ZDLSF01–09 to SW), and the CAS Key Laboratory of Brain Connectome and Manipulation (2019DP173024 to WW).
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
WW designed and supervised the project. JX wrote the original draft. All authors reviewed and edited the text and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AdellA. (2020). Brain NMDA receptors in schizophrenia and depression. Biomolecules.10, 947. 10.3390/biom10060947
2
AggletonJ. P.NelsonA. J. D. (2020). Distributed interactive brain circuits for object-in-place memory: a place for time?Brain Neurosci. Adv.4, 2398212820933471. 10.1177/2398212820933471
3
AkilliogluK.Babar MelikE.MelikE.KocahanS. (2012). The investigation of neonatal MK-801 administration and physical environmental enrichment on emotional and cognitive functions in adult Balb/c mice. Pharmacol. Biochem. Behav.102, 407–414. 10.1016/j.pbb.2012.06.006
4
BatinicB. (2019). Cognitive models of positive and negative symptoms of schizophrenia and implications for treatment. Psychiatr. Danub.31, 181–184.
5
BenskeT. M.MuT. W.WangY. J. (2022). Protein quality control of N-methyl-D-aspartate receptors. Front. Cell Neurosci.16, 907560. 10.3389/fncel.2022.907560
6
BernaudV. E.HiroiR.PoissonM. L.CastanedaA. J.KirshnerZ. Z.GibbsR. B.et al. (2021). Age impacts the burden that reference memory imparts on an increasing working memory load and modifies relationships with cholinergic activity. Front. Behav. Neurosci.15, 610078. 10.3389/fnbeh.2021.610078
7
BurrowsE. L.McOmishC. E.BuretL. S.Van den BuuseM.HannanA. J. (2015). Environmental enrichment ameliorates behavioral impairments modeling schizophrenia in mice lacking metabotropic glutamate receptor 5. Neuropsychopharmacology.40, 1947–1956. 10.1038/npp.2015.44
8
CorteseG. P.OlinA.O'RiordanK.HullingerR.BurgerC. (2018). Environmental enrichment improves hippocampal function in aged rats by enhancing learning and memory, LTP, and mGluR5-Homer1c activity. Neurobiol. Aging.63, 1–11. 10.1016/j.neurobiolaging.2017.11.004
9
CroftonE. J.ZhangY.GreenT. A. (2015). Inoculation stress hypothesis of environmental enrichment. Neurosci. Biobehav. Rev.49, 19–31. 10.1016/j.neubiorev.2014.11.017
10
DenningerJ. K.SmithB. M.KirbyE. D. (2018). Novel object recognition and object location behavioral testing in mice on a budget. J. Vis. Exp.10.3791/58593. [Epub ahead of print].
11
DietzA. G.GoldmanS. A.NedergaardM. (2020). Glial cells in schizophrenia: a unified hypothesis. Lancet Psychiatry.7, 272–281. 10.1016/S2215-0366(19)30302-5
12
FaatehiM.BasiriM.NezhadiA.ShabaniM.Masoumi-ArdakaniY.SoltaniZ.et al. (2019). Early enriched environment prevents cognitive impairment in an animal model of schizophrenia induced by MK-801: role of hippocampal BDNF. Brain Res.1711, 115–119. 10.1016/j.brainres.2019.01.023
13
FuruieH.YamadaK.IchitaniY. (2019). Differential effects of N-methyl-D-aspartate receptor blockade during the second and third postnatal weeks on spatial working and reference memory in adult rats. Brain Res.1721, 146339. 10.1016/j.brainres.2019.146339
14
GaoZ. K.ShenX. Y.HanY.GuoY. S.YuanM.BiX. (2022). Enriched environment effects on myelination of the central nervous system: role of glial cells. Neural. Plast.2022, 5766993. 10.1155/2022/5766993
15
GirdlerS. J.ConfinoJ. E.WoesnerM. E. (2019). Exercise as a treatment for schizophrenia: a review. Psychopharmacol. Bull.49, 56–69.
16
GrilliM.ZappettiniS.ZanardiA.LagomarsinoF.PittalugaA.ZoliM.et al. (2009). Exposure to an enriched environment selectively increases the functional response of the pre-synaptic NMDA receptors which modulate noradrenaline release in mouse hippocampus. J. Neurochem.110, 1598–1606. 10.1111/j.1471-4159.2009.06265.x
17
GubertC.HannanA. J. (2019). Environmental enrichment as an experience-dependent modulator of social plasticity and cognition. Brain Res.1717, 1–14. 10.1016/j.brainres.2019.03.033
18
GuoC.LiuY.FangM. S.LiY.LiW.MahamanY. A. R.et al. (2020). ω-3PUFAs improve cognitive impairments through Ser133 phosphorylation of CREB upregulating BDNF/TrkB signal in schizophrenia. Neurotherapeutics.17, 1271–1286. 10.1007/s13311-020-00859-w
19
HansenK. B.YiF.PerszykR. E.FurukawaH.WollmuthL. P.GibbA. J.et al. (2018). Structure, function, and allosteric modulation of NMDA receptors. J. Gen. Physiol.150, 1081–1105. 10.1085/jgp.201812032
20
HarbM.JaguschJ.DurairajaA.EndresT.LeßmannV.FendtM. (2021). BDNF haploinsufficiency induces behavioral endophenotypes of schizophrenia in male mice that are rescued by enriched environment. Transl. Psychiatry.11, 233. 10.1038/s41398-021-01365-z
21
JauharS.JohnstoneM.McKennaP. J. (2022). Schizophrenia. Lancet.399, 473–486. 10.1016/S0140-6736(21)01730-X
22
KempermannG. (2019). Environmental enrichment, new neurons and the neurobiology of individuality. Nat. Rev. Neurosci.20, 235–245. 10.1038/s41583-019-0120-x
23
KhakpoorM.VaseghiS.Mohammadi-Mahdiabadi-HasaniM. H.NasehiM. (2021). The effect of GABA-B receptors in the basolateral amygdala on passive avoidance memory impairment induced by MK-801 in rats. Behav. Brain Res.409, 113313. 10.1016/j.bbr.2021.113313
24
KimH.ParkJ. Y.KimK. K. (2018). Spatial learning and memory using a radial arm maze with a head-mounted display. Psychiatry Investig.15, 935–944. 10.30773/pi.2018.06.28.3
25
KocahanS.AkilliogluK.BinokayS.SencarL.PolatS. (2013). The effects of N-Methyl-D-Aspartate receptor blockade during the early neurodevelopmental period on emotional behaviors and cognitive functions of adolescent Wistar rats. Neurochem. Res.38, 989–996. 10.1007/s11064-013-1008-1
26
Kruk-SlomkaM.BialaG. (2016). CB1 receptors in the formation of the different phases of memory-related processes in the inhibitory avoidance test in mice. Behav. Brain Res.301, 84–95. 10.1016/j.bbr.2015.12.023
27
KurzinaN. P.AristovaI. Y.VolnovaA. B.GainetdinovR. R. (2020). Deficit in working memory and abnormal behavioral tactics in dopamine transporter knockout rats during training in the 8-arm maze. Behav. Brain Res.390, 112642. 10.1016/j.bbr.2020.112642
28
LiJ.YangS.LiuX.HanY.LiY.FengJ.et al. (2019). Hypoactivity of the lateral habenula contributes to negative symptoms and cognitive dysfunction of schizophrenia in rats. Exp. Neurol.318, 165–173. 10.1016/j.expneurol.2019.05.005
29
LiW.MaoZ.BoQ.SunY.WangZ.WangC. (2021). Prepulse inhibition in first-degree relatives of schizophrenia patients: a systematic review. Early Interv. Psychiatry.15, 652–661. 10.1111/eip.13003
30
LiY. X.YeZ. H.ChenT.JiaX. F.HeL. (2018). The effects of donepezil on phencyclidine-induced cognitive deficits in a mouse model of schizophrenia. Pharmacol. Biochem. Behav.175, 69–76. 10.1016/j.pbb.2018.09.006
31
LissnerL. J.WartchowK. M.ToniazzoA. P.GonçalvesC. A.RodriguesL. (2021). Object recognition and Morris water maze to detect cognitive impairment from mild hippocampal damage in rats: a reflection based on the literature and experience. Pharmacol. Biochem. Behav.210, 173273. 10.1016/j.pbb.2021.173273
32
Livingston-ThomasJ.NelsonP.KarthikeyanS.AntonescuS.JeffersM. S.MarzoliniS.et al. (2016). Exercise and environmental enrichment as enablers of task-specific neuroplasticity and stroke recovery. Neurotherapeutics.13, 395–402. 10.1007/s13311-016-0423-9
33
LundgaardI.LuzhynskayaA.StockleyJ. H.WangZ.EvansK. A.SwireM.et al. (2013). Neuregulin and BDNF induce a switch to NMDA receptor-dependent myelination by oligodendrocytes. PLoS Biol.11, e1001743. 10.1371/journal.pbio.1001743
34
MaasD. A.EijsinkV. D.SpoelderM.van HultenJ. A.De WeerdP.HombergJ. R.et al. (2020). Interneuron hypomyelination is associated with cognitive inflexibility in a rat model of schizophrenia. Nat. Commun.11, 2329. 10.1038/s41467-020-16218-4
35
MacQueenD. A.YoungJ. W. (2020). The D2-family receptor agonist bromocriptine but, not nicotine, reverses NMDA receptor antagonist-induced working memory deficits in the radial arm maze in mice. Neurobiol. Learn. Mem.168, 107159. 10.1016/j.nlm.2020.107159
36
MahmoudS.GharagozlooM.SimardC.GrisD. (2019). Astrocytes maintain glutamate homeostasis in the CNS by controlling the balance between glutamate uptake and release. Cells.8, 184. 10.3390/cells8020184
37
MarquesT. R.AshokA. H.AngelescuI.BorganF.MyersJ.Lingford-HughesA.et al. (2021). GABA-A receptor differences in schizophrenia: a positron emission tomography study using [(11)C]Ro154513. Mol. Psychiatry.26, 2616–2625. 10.1038/s41380-020-0711-y
38
MehrotraS.PierceM. L.CaoZ.JabbaS. V.GerwickW. H.MurrayT. F. (2022). Antillatoxin-stimulated neurite outgrowth involves the brain-derived neurotrophic factor (BDNF)-tropomyosin related kinase B (TrkB) signaling pathway. J. Nat. Prod.85, 562–571. 10.1021/acs.jnatprod.1c01001
39
MeiJ.KohlerJ.WinterY.SpiesC.EndresM.BannekeS.et al. (2020). Automated radial 8-arm maze: a voluntary and stress-free behavior test to assess spatial learning and memory in mice. Behav. Brain Res.381, 112352. 10.1016/j.bbr.2019.112352
40
Murueta-GoyenaA.Morera-HerrerasT.MiguelezC.Gutiérrez-CeballosA.UgedoL.LafuenteJ. V.et al. (2019). Effects of adult enriched environment on cognition, hippocampal-prefrontal plasticity and NMDAR subunit expression in MK-801-induced schizophrenia model. Eur. Neuropsychopharmacol.29, 590–600. 10.1016/j.euroneuro.2019.03.009
41
Murueta-GoyenaA.OrtuzarN.GargiuloP.LafuenteJ. V.BengoetxeaH. (2018). Short-term exposure to enriched environment in adult rats restores MK-801-induced cognitive deficits and GABAergic interneuron immunoreactivity loss. Mol. Neurobiol.55, 26–41. 10.1007/s12035-017-0715-z
42
Murueta-GoyenaA.OrtuzarN.LafuenteJ. V.BengoetxeaH. (2020). Enriched environment reverts somatostatin interneuron loss in MK-801 model of schizophrenia. Mol. Neurobiol.57, 125–134. 10.1007/s12035-019-01762-y
43
NakazawaK.SapkotaK. (2020). The origin of NMDA receptor hypofunction in schizophrenia. Pharmacol. Ther.205, 107426. 10.1016/j.pharmthera.2019.107426
44
NishiyamaK.SuzukiH.HarasawaT.SuzukiN.KurimotoE.KawaiT.et al. (2017). FTBMT, a novel and selective GPR52 agonist, demonstrates antipsychotic-like and procognitive effects in rodents, revealing a potential therapeutic agent for schizophrenia. J. Pharmacol. Exp. Ther.363, 253–264. 10.1124/jpet.117.242925
45
NotterT. (2021). Astrocytes in schizophrenia. Brain Neurosci. Adv.5, 23982128211009148. 10.1177/23982128211009148
46
NozariM.MansouriF. A.ShabaniM.NozariH.AtapourN. (2015a). Postnatal MK-801 treatment of female rats impairs acquisition of working memory, but not reference memory in an eight-arm radial maze; no beneficial effects of enriched environment. Psychopharmacology.232, 2541–2550. 10.1007/s00213-015-3890-5
47
NozariM.ShabaniM.FarhangiA. M.MazhariS.AtapourN. (2015b). Sex-specific restoration of MK-801-induced sensorimotor gating deficit by environmental enrichment. Neuroscience.299, 28–34. 10.1016/j.neuroscience.2015.04.050
48
NozariM.ShabaniM.HadadiM.AtapourN. (2014). Enriched environment prevents cognitive and motor deficits associated with postnatal MK-801 treatment. Psychopharmacology.231, 4361–4370. 10.1007/s00213-014-3580-8
49
NozariM.SuzukiT.RosaM. G.YamakawaK.AtapourN. (2017). The impact of early environmental interventions on structural plasticity of the axon initial segment in neocortex. Dev. Psychobiol.59, 39–47. 10.1002/dev.21453
50
PlatakiM. E.DiskosK.SougklakosC.VelissariouM.GeorgilisA.StavroulakiV.et al. (2021). Effect of neonatal treatment with the NMDA receptor antagonist, MK-801, during different temporal windows of postnatal period in adult prefrontal cortical and hippocampal function. Front. Behav. Neurosci.15, 689193. 10.3389/fnbeh.2021.689193
51
PradesR.Munarriz-CuezvaE.UrigüenL.Gil-PisaI.GómezL.MendietaL.et al. (2017). The prolyl oligopeptidase inhibitor IPR19 ameliorates cognitive deficits in mouse models of schizophrenia. Eur. Neuropsychopharmacol.27, 180–191. 10.1016/j.euroneuro.2016.11.016
52
RahatiM.NozariM.EslamiH.ShabaniM.BasiriM. (2016). Effects of enriched environment on alterations in the prefrontal cortex GFAP- and S100B-immunopositive astrocytes and behavioral deficits in MK-801-treated rats. Neuroscience.326, 105–116. 10.1016/j.neuroscience.2016.03.065
53
Ramírez-RodríguezG. B.Vega-RiveraN. M.Meneses-San JuanD.Ortiz-LópezL.Estrada-CamarenaE. M.Flores-RamosM. (2021). Short daily exposure to environmental enrichment, fluoxetine, or their combination reverses deterioration of the coat and anhedonia behaviors with differential effects on hippocampal neurogenesis in chronically stressed mice. Int. J. Mol. Sci.22, 10976. 10.3390/ijms222010976
54
RatajczakP.NowakowskaE.KusK.DanielewiczR.HermanS.WozniakA. (2015). Neuroleptics and enrichment environment treatment in memory disorders and other central nervous system function observed in prenatally stressed rats. Hum. Exp. Toxicol.34, 526–537. 10.1177/0960327114543934
55
RostamiS.HaghparastA.FayazmilaniR. (2021). The downstream effects of forced exercise training and voluntary physical activity in an enriched environment on hippocampal plasticity in preadolescent rats. Brain Res.1759, 147373. 10.1016/j.brainres.2021.147373
56
Sampedro-PiqueroP.Álvarez-SuárezP.Moreno-FernándezR. D.García-CastroG.CuestaM.BegegaA. (2018). Environmental enrichment results in both brain connectivity efficiency and selective improvement in different behavioral tasks. Neuroscience.388, 374–383. 10.1016/j.neuroscience.2018.07.036
57
SearsS. M.HewettS. J. (2021). Influence of glutamate and GABA transport on brain excitatory/inhibitory balance. Exp. Biol. Med.246, 1069–1083. 10.1177/1535370221989263
58
ShahzadS.AhmadS.MadihaS.KhaliqS.LiaquatL.SadirS.et al. (2017). Dizocilpine induced psychosis-like behavior in rats: a possible animal model with full spectrum of schizophrenia. Pak. J. Pharm. Sci.30, 2423–2427.
59
TakumaK.MaedaY.AgoY.IshihamaT.TakemotoK.NakagawaA.et al. (2014). An enriched environment ameliorates memory impairments in PACAP-deficient mice. Behav. Brain Res.272, 269–278. 10.1016/j.bbr.2014.07.005
60
Tarrés-GatiusM.López-HillX.Miquel-RioL.CastarlenasL.FabiusS.SantanaN.et al. (2022). Discrimination of motor and sensorimotor effects of phencyclidine and MK-801: Involvement of GluN2C-containing NMDA receptors in psychosis-like models. Neuropharmacology.213, 109079. 10.1016/j.neuropharm.2022.109079
61
ValesK.HolubovaK. (2021). Minireview: animal model of schizophrenia from the perspective of behavioral pharmacology: effect of treatment on cognitive functions. Neurosci. Lett.761, 136098. 10.1016/j.neulet.2021.136098
62
van der StaayF. J.RuttenK.ErbC.BloklandA. (2011). Effects of the cognition impairer MK-801 on learning and memory in mice and rats. Behav. Brain Res.220, 215–229. 10.1016/j.bbr.2011.01.052
63
WallachJ.KangH.ColestockT.MorrisH.BortolottoZ. A.CollingridgeG. L.et al. (2016). Pharmacological investigations of the dissociative 'legal highs' diphenidine, methoxphenidine and analogues. PLoS ONE.11, e0157021. 10.1371/journal.pone.0157021
64
WangX.HuY.LiuW.MaY.ChenX.XueT.et al. (2021). Molecular basis of GABA hypofunction in adolescent schizophrenia-like animals. Neural. Plast.2021, 9983438. 10.1155/2021/9983438
65
WinshipI. R.DursunS. M.BakerG. B.BalistaP. A.KandrataviciusL.Maia-de-OliveiraJ. P.et al. (2019). An overview of animal models related to schizophrenia. Can. J. Psychiatry.64, 5–17. 10.1177/0706743718773728
66
WuQ.WangX.WangY.LongY. J.ZhaoJ. P.WuR. R. (2021). Developments in biological mechanisms and treatments for negative symptoms and cognitive dysfunction of schizophrenia. Neurosci. Bull.37, 1609–1624. 10.1007/s12264-021-00740-6
67
XiaoX.XuX.LiF.XieG.ZhangT. (2019). Anti-inflammatory treatment with β-asarone improves impairments in social interaction and cognition in MK-801 treated mice. Brain Res. Bull.150, 150–159. 10.1016/j.brainresbull.2019.05.017
68
YuW.ZhuH.WangY.LiG.WangL.LiH. (2015). Reactive transformation and increased BDNF signaling by hippocampal astrocytes in response to MK-801. PLoS ONE.10, e0145651. 10.1371/journal.pone.0145651
69
YuW.ZhuM.FangH.ZhouJ.YeL.BianW.et al. (2019). Risperidone reverses the downregulation of BDNF in hippocampal neurons and MK801-induced cognitive impairment in rats. Front. Behav. Neurosci.13, 163. 10.3389/fnbeh.2019.00163
70
ZahiriH.RostampourM.KhakpourB.RohampourK. (2021). The effect of ghrelin injection in the CA1 region of hippocampus on the MK801- induced memory impairment in wistar rats. Behav. Brain Res.405, 113209. 10.1016/j.bbr.2021.113209
71
ZhangX.YuanM.YangS.ChenX.WuJ.WenM.et al. (2021). Enriched environment improves post-stroke cognitive impairment and inhibits neuroinflammation and oxidative stress by activating Nrf2-ARE pathway. Int. J. Neurosci.131, 641–649. 10.1080/00207454.2020.1797722
72
ZhangY.WangG.WangL.ZhaoJ.HuangR.XiongQ. (2018). The short-term improvements of enriched environment in behaviors and pathological changes of APP/PS1 mice via regulating cytokines. Hum. Vaccin. Immunother.14, 2003–2011. 10.1080/21645515.2018.1463944
73
ZhuX.GraceA. A. (2021). Prepubertal environmental enrichment prevents dopamine dysregulation and hippocampal hyperactivity in MAM schizophrenia model rats. Biol. Psychiatry.89, 298–307. 10.1016/j.biopsych.2020.09.023
74
ZhuX.GraceA. A. (2022). Use of prepubertal environment enrichment to prevent dopamine dysregulation in a neurodevelopmental rat model of schizophrenia risk. STAR Protoc.3, 101215. 10.1016/j.xpro.2022.101215
Summary
Keywords
schizophrenia, environmental enrichment, MK-801, cognitive symptoms, mechanism
Citation
Xu J, Li Y, Tian B, Liu H, Wu S and Wang W (2022) The effects and mechanism of environmental enrichment on MK-801 induced cognitive impairment in rodents with schizophrenia. Front. Cell. Neurosci. 16:1024649. doi: 10.3389/fncel.2022.1024649
Received
22 August 2022
Accepted
13 September 2022
Published
29 September 2022
Volume
16 - 2022
Edited by
Gaston Calfa, Universidad Nacional de Córdoba, Argentina
Reviewed by
Harkaitz Bengoetxea, University of the Basque Country, Spain; A. J. Baucum, Indiana University Bloomington, United States
Updates
Copyright
© 2022 Xu, Li, Tian, Liu, Wu and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wenting Wang wwt0657@fmmu.edu.cn
This article was submitted to Cellular Neurophysiology, a section of the journal Frontiers in Cellular Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.